MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317771 | Name: Encainide Hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Encainide Hydrochloride is a class Ic antiarrhythmic agent. It is no longer used because of its frequent proarrhythmic side effects. One of the anti-arrhythmia, it blocks voltage-gated sodium channels and slows conduction within the His-Purkinje system and myocardium. Encainide is a non-chiral antiarrhythmic and benzanilide derivative.

Chemical Structure

Encainide Hydrochloride
Encainide Hydrochloride
CAS# 66794-74-9

Theoretical Analysis

MedKoo Cat#: 317771

Name: Encainide Hydrochloride

CAS#: 66794-74-9

Chemical Formula: C22H29ClN2O2

Exact Mass:

Molecular Weight: 388.93

Elemental Analysis: C 67.94; H, 7.52; Cl, 9.12; N, 7.20; O, 8.23

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Encainide Hydrochloride; Encainide HCl; Enkaid; 66794-74-9; CHEBI:59880; Encainide, (+)-Isomer; Encainide, (-)-Isomer; Enkaid MJ 9067; MJ-9067;
IUPAC/Chemical Name
4-methoxy-N-[2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl]benzamide;hydrochloride
InChi Key
OJIIZIWOLTYOBS-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H28N2O2.ClH/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18;/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25);1H
SMILES Code
CN1CCCCC1CCC2=CC=CC=C2NC(=O)C3=CC=C(C=C3)OC.Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 388.93 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chase SL, Sloskey GE. Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents. Clin Pharm. 1987 Nov;6(11):839-50. Review. Erratum in: Clin Pharm 1988 Apr;7(4):269. PubMed PMID: 3119276. 2: Treatment of life-threatening ventricular tachycardia with encainide hydrochloride in patients with left ventricular dysfunction. The Encainide-Ventricular Tachycardia Study Group. Am J Cardiol. 1988 Sep 15;62(9):571-5. PubMed PMID: 3137797. 3: Myerburg RJ, Kessler KM, Cox MM, Huikuri H, Terracall E, Interian A Jr, Fernandez P, Castellanos A. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. Circulation. 1989 Dec;80(6):1571-9. PubMed PMID: 2480856. 4: Horowitz LN. Encainide in lethal ventricular arrhythmias evaluated by electrophysiologic testing and decrease in symptoms. Am J Cardiol. 1986 Aug 29;58(5):83C-86C. Review. PubMed PMID: 3092624. 5: Morganroth J, Somberg JC, Pool PE, Hsu PH, Lee IK, Durkee J, Salerno DM. Comparative study of encainide and quinidine in the treatment of ventricular arrhythmias. J Am Coll Cardiol. 1986 Jan;7(1):9-16. Erratum in: J Am Coll Cardiol 1986 Oct;8(4):992. PubMed PMID: 3079781. 6: Svensson CK, Knowlton PW. Effect of encainide on in vivo drug metabolism in the rat. Res Commun Chem Pathol Pharmacol. 1987 May;56(2):285-8. PubMed PMID: 3110886. 7: Bartek MJ, Mayol RF, Boarman MP, Gammans RE, Gallo DG. Analysis of encainide and metabolites in plasma and urine by high-performance liquid chromatography. Ther Drug Monit. 1988;10(4):446-52. PubMed PMID: 3144068. 8: Anderson JL, Platia EV, Hallstrom A, Henthorn RW, Buckingham TA, Carlson MD, Carson PE. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Circulation. 1994 Dec;90(6):2843-52. PubMed PMID: 7994829. 9: Case CL, Hewett KW, Gillette PC. Developmental electrophysiology of encainide and its major metabolites on the Purkinje fiber action potential. Biol Neonate. 1994;66(6):330-8. PubMed PMID: 7727615. 10: Wallace AA, Stupienski RF 3rd, Kothstein T, Gehret JR, Lynch JJ Jr. Demonstration of proarrhythmic activity with the class IC antiarrhythmic agent encainide in a canine model of previous myocardial infarction. J Cardiovasc Pharmacol. 1993 Mar;21(3):397-404. PubMed PMID: 7681500. 11: Funck-Brentano C, Thomas G, Jacqz-Aigrain E, Poirier JM, Simon T, Béréziat G, Jaillon P. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther. 1992 Nov;263(2):780-6. PubMed PMID: 1432700. 12: Winter WE, Funahashi M, Koons J. Encainide-induced diabetes: analysis of islet cell function. Res Commun Chem Pathol Pharmacol. 1992 Jun;76(3):259-68. PubMed PMID: 1636050. 13: Buchanan LV, Kabell G, Turcotte UM, Brunden MN, Gibson JK. Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide. J Cardiovasc Pharmacol. 1992 Feb;19(2):256-63. PubMed PMID: 1376795. 14: Hilleman DE, Mohiuddin SM, Destache CJ, Stoysich AM, Nipper HC, Malesker MA. Impact of food on the bioavailability of encainide. J Clin Pharmacol. 1992 Sep;32(9):833-7. PubMed PMID: 1430302. 15: Akiyama T, Pawitan Y, Greenberg H, Kuo CS, Reynolds-Haertle RA. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol. 1991 Dec 15;68(17):1551-5. PubMed PMID: 1720917. 16: Lee JH, Rosen MR. Use-dependent actions and effects on transmembrane action potentials of flecainide, encainide, and ethmozine in canine Purkinje fibers. J Cardiovasc Pharmacol. 1991 Aug;18(2):285-92. PubMed PMID: 1717791. 17: Roden DM, Lee JT, Woosley RL, Echt DS. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation. Circulation. 1989 Nov;80(5):1247-58. PubMed PMID: 2805262. 18: Dawson AK, Roden DM, Duff HJ, Woosley RL, Smith RF. Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog. Am J Cardiol. 1984 Sep 1;54(6):654-8. PubMed PMID: 6475789. 19: Duff HJ, Dawson AK, Roden DM, Oates JA, Smith RF, Woosley RL. Electrophysiologic actions of O-demethyl encainide: an active metabolite. Circulation. 1983 Aug;68(2):385-91. PubMed PMID: 6861313. 20: Ware DL, Lee JT, Murray KT, Hanyok JJ, Roden DM, Echt DS. Intravenous 3-methoxy-O-desmethyl-encainide in reentrant supraventricular tachycardia: a randomized double-blind placebo-controlled trial in patients undergoing EP study. Pacing Clin Electrophysiol. 1991 Sep;14(9):1343-50. PubMed PMID: 1720527.

View History

SU 4313

SU 4313

New Featured